Business Wire

Q4 Inc. Releases Next Generation Investor Conference Features for its Rapidly Growing Investment Banking Client Base

9.12.2021 17:00:00 EET | Business Wire | Press release

Share

Q4 Inc. (TSX: QFOR) (“Q4" or “the Company”), a leading capital markets communications platform, today announced the release of a suite of new features for its Capital Markets Event (“CME”) platform, launched earlier this year, and designed to provide virtual and in-person events for investment banking hosted investor conferences.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211209005633/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Branded Event Registration (Graphic: Business Wire)

Starting in 2020, Q4 has experienced unprecedented demand from investment banks to create, host and deliver investor conferences for their buy-side clients. Since that time, Q4 has hosted thousands of market participants across investor conferences, reverse roadshows and corporate investor days and has established the bar by which all other capital markets and financial service events are measured. Building on its rapidly expanding footprint in the investment banking market, Q4 continues to enhance the CME platform in its partnership with corporate access teams at the world’s leading investment banks.

New capabilities recently added include sophisticated event registration, easy scheduling for meetings of all sizes, whether they are 1:1, 2:1 or larger group meetings, and meeting management data and analytics to assist corporate access teams successfully envision, plan and execute these critical events. These new features are embedded within Q4’s event platform, as well as API integrated into Zoom, Microsoft Teams and other technologies, delivering a seamless conference experience for all participants.

Specifically, these new features provide new registration functionality, which allows corporate and investor participants to submit their availability, and allows investors to indicate which corporate issuers they are interested in meeting with in priority order and preference for 1:1, 2:1 or a larger group meeting. This information is directly funneled to the internal scheduling tool, which makes scheduling significantly easier and updates automatically as participant availability changes.

Additionally, the Platform has new features that allow for meeting details to be easily added, edited and made available to all participants so that everyone is easily informed about the type of meeting, attendee information, and easy links for meeting access.

Finally, this upgrade provides critical data around scheduling as well as session and meeting attendance, helping corporate access teams determine which corporate issuers and investors may need additional meetings to enrich their experience, and require priority focus.

“We launched our Capital Markets Events (CME) platform with the vision of connecting all capital markets participants in their discovery, communications and engagement with each other,” said Darrell Heaps, CEO of Q4. “We are excited to enhance the capabilities of our platform, and deliver an elevated experience for our investment bank customers. We will continue to add features to our rapidly evolving solution, as we lead the digital transformation of corporate access engagements that connect all sides of the capital markets.”

To learn more about the Q4 CME platform, click here.

About Q4, Inc.

Q4 Inc. (Q4), is a leading capital markets communications platform that is transforming the way publicly traded companies, investors, and investment banks make decisions to efficiently discover, communicate, and engage with each other. The Q4 end-to-end technology platform facilitates interactions across the capital markets through its IR website products, virtual events solutions, capital markets customer relationship management solution, and shareholder and market analytics tools. The firm is a trusted partner to over 2,600 public companies as well as top tier investment banks. Q4 is based in Toronto, with offices in New York and London.

To learn more, visit: www.q4inc.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Inquiries:
Karen Greene media@q4inc.com

IR Inquiries:
Matt Tractenberg ir@q4inc.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FuzeBox AI Named Founding Co-Author of SPUR Coalition Technical Committee on Verifying AI Content Use5.10.2026 16:00:00 EEST | Press release

FuzeBox AI has been named by the SPUR Coalition, an international nonprofit of 37 news and media organizations, as one of four founding co-authors of its Evidence Profile Technical Committee, adopted Sept. 2, 2026, to draft an evidence profile for SPUR's Content Telemetry standard: a way for publishers to verify AI usage reports without depending on the reporting company's cooperation. Under SPUR's current standard, AI companies self-report their content use. A company that skips reporting leaves no record, and publishers can't check what they do receive. On July 10, 2026, FuzeBox proposed its Verified Provenance Telemetry Standard (VPTS): publishers seed content with detectable markers, then verify their appearance in AI outputs via an auditable ledger, with no change to SPUR's standard. Within 48 hours, three organizations filed related proposals: ProRata on usage magnitude, Encypher CEO Erik Svilich on the verification question FuzeBox raised, and LicenseFoundry on portable proof of

Mary Kay Introduces the K-Beauty Texture Edit5.10.2026 15:02:00 EEST | Press release

Mary Kay Inc.,the iconic beauty giant announced today the launch of the K-Beauty Texture Edit, aspecial-edition skin care collection available while supplies last. The collection builds on the momentum of the company's largest consumer-facing global brand platform, Beauty Is More Beautiful Shared™ which launched in September. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261005600130/en/ Mary Kay's Special Edition K-Beauty Texture Edit is a trend-forward collection which includes three Korea-made products: the Mary Kay® Melt-In Cleansing Balm, Mary Kay® Snail Gel Face Patches and Mary Kay® Collagen Moisturizing Gel. (Image Credit: Mary Kay Inc.) Inspired by Korea's globally influential skin care and self-care philosophy designed to bring playful textures, innovative ingredients, and elevated beauty experiences, the K-Beauty Texture Editwas designed to resonate with a global cultural beauty movement captivating the next gene

GE HealthCare to Acquire SOFIE Biosciences, Establishing a 'Final Mile' Footprint for PET Radiopharmaceutical Supply in the U.S.5.10.2026 15:00:00 EEST | Press release

GE HealthCare (Nasdaq: GEHC) today announced a definitive agreement to acquire SOFIE Biosciences, a leading U.S.-based CMO for PET radiopharmaceuticals, from Trilantic North America, for a purchase price of $945 million paid in cash. The transaction is expected to close in the first half of 2027, subject to closing conditions, including regulatory approvals, at which time SOFIE Biosciences will become part of GE HealthCare’s PDx segment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261005273717/en/ SOFIE Biosciences has 15 CMO sites across the U.S., manufacturing PET radiopharmaceutical products The acquisition of SOFIE Biosciences establishes a footprint for GE HealthCare in the time-critical ‘final mile’ of U.S. PET radiopharmaceutical supply, while also enabling PDx to participate in other high growth areas outside its own product portfolio. With a U.S. network of 15 CMO sites operating 21 cyclotrons, and a theranostics

Henkell Freixenet Strengthens Premium Dealcoholized Sparkling Wine Production with Solos' Patented Aroma Recovery System5.10.2026 14:24:00 EEST | Press release

Henkell Freixenet is expanding its premium dealcoholized sparkling wine production capabilities through the deployment of Solos Technology's patented Aroma Recovery System (ARS) at its Wiesbaden production site, the Group’s expertise centre for alcohol-free production. The installation represents a significant investment in next-generation dealcoholized sparkling wine production, helping preserve the natural aroma and sensory identity of the original wines. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261005959301/en/ Fürst von Metternich Riesling Alcohol-free on the bottling line, one of the first products in Henkell Freixenet’s portfolio developed in collaboration with Solos Technology. The project combines Henkell Freixenet's longstanding winemaking expertise with Solos' proprietary dealcoholization and patented aroma recovery technology. With 30 years of experience in producing alcohol-free sparkling wines, Henkell Fre

Croma-Pharma Expands Its Portfolio in Canada With saypha ® lips Lidocaine and Exprecell™5.10.2026 14:12:00 EEST | Press release

Croma-Pharma continues to build its portfolio in Canada, adding saypha® lips Lidocaine, a hyaluronic acid filler for lip augmentation,1 and Exprecell™, a medical device for the preparation of autologous PRP | Fluid-PRF.2 Both are distributed by Renellence, Croma's partner in Canada since 2025. The two additions reflect Croma's broader approach: pairing established hyaluronic acid expertise with autologous, regenerative technologies. Together, they give practitioners options across both aesthetic and regenerative treatment categories, from a single trusted source. "With saypha® lips Lidocaine and Exprecell™, we're giving Canadian practitioners a wider set of tools for facial aesthetics and regenerative treatments, each held to the same standard of precision and safety," said Andreas Prinz, Chief Executive Officer of Croma-Pharma GmbH. Renellence has distributed Croma's Saypha® hyaluronic acid filler range in Canada since October 2025, alongside medical education and training for Canadia

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye